CRIS Current Research Information System

VIANELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.540
AS - Asia 4.894
EU - Europa 3.361
AF - Africa 286
SA - Sud America 262
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.355
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.459
SG - Singapore 1.403
VN - Vietnam 1.244
CN - Cina 1.240
GB - Regno Unito 750
IT - Italia 529
SE - Svezia 521
DE - Germania 456
HK - Hong Kong 302
IN - India 241
FR - Francia 218
RU - Federazione Russa 181
BR - Brasile 176
IE - Irlanda 154
NL - Olanda 107
FI - Finlandia 94
KR - Corea 93
JP - Giappone 85
CI - Costa d'Avorio 83
ZA - Sudafrica 71
TG - Togo 69
UA - Ucraina 66
EE - Estonia 56
CA - Canada 50
BG - Bulgaria 42
JO - Giordania 40
BE - Belgio 39
PH - Filippine 38
CH - Svizzera 37
TH - Thailandia 28
AR - Argentina 27
AT - Austria 23
BD - Bangladesh 23
ID - Indonesia 23
PL - Polonia 23
NG - Nigeria 21
TW - Taiwan 21
MX - Messico 20
TR - Turchia 19
EC - Ecuador 17
PK - Pakistan 17
IR - Iran 15
CO - Colombia 13
IQ - Iraq 13
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
ES - Italia 10
LT - Lituania 10
AU - Australia 9
PY - Paraguay 9
SC - Seychelles 9
PE - Perù 8
GR - Grecia 7
CL - Cile 6
EG - Egitto 6
ET - Etiopia 6
MA - Marocco 6
DZ - Algeria 5
LB - Libano 5
LV - Lettonia 5
MY - Malesia 5
RO - Romania 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
AL - Albania 3
DK - Danimarca 3
IL - Israele 3
JM - Giamaica 3
MK - Macedonia 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CG - Congo 2
CR - Costa Rica 2
CY - Cipro 2
GT - Guatemala 2
HR - Croazia 2
KE - Kenya 2
NZ - Nuova Zelanda 2
OM - Oman 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GF - Guiana Francese 1
GH - Ghana 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MG - Madagascar 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 14.351
Salva come PNG Salva come JPEG
Città #
Singapore 962
Southend 635
Ashburn 632
Fairfield 555
Chandler 464
San Jose 372
Hong Kong 288
Seattle 242
Ho Chi Minh City 240
Woodbridge 236
Hanoi 233
Cambridge 232
Houston 229
Wilmington 216
Dong Ket 205
Ann Arbor 185
Santa Clara 182
Hefei 174
Beijing 170
Princeton 161
Dublin 152
Boardman 111
Bologna 111
Lauterbourg 88
Los Angeles 88
Abidjan 83
Dallas 74
Helsinki 74
Seoul 74
Lomé 69
Tokyo 69
Nanjing 66
Westminster 64
New York 57
Padova 54
Milan 52
Bremen 51
Munich 49
Berlin 44
Hyderabad 44
Buffalo 43
Council Bluffs 42
Sofia 42
Amman 40
Jinan 40
Brussels 39
Shenyang 39
Turin 39
Frankfurt am Main 37
Saint Petersburg 35
Cornaredo 32
Haiphong 32
Jacksonville 32
Bern 31
Da Nang 30
Redmond 28
Redondo Beach 27
Guangzhou 26
San Diego 24
Shanghai 23
Changsha 20
Chicago 20
London 20
Abeokuta 18
Johannesburg 18
Nanchang 18
Zhengzhou 18
Bengaluru 17
Amsterdam 16
Falls Church 16
Hangzhou 16
Hebei 16
Jakarta 16
Nuremberg 16
Phoenix 16
Toronto 16
Warsaw 16
Orem 15
São Paulo 15
Can Tho 14
Des Moines 14
Tianjin 14
Biên Hòa 13
Montreal 13
Rome 13
Brooklyn 12
Menlo Park 12
Falkenstein 11
Florence 11
Lappeenranta 11
Medford 11
Olalla 11
Redwood City 11
Dearborn 10
Fremont 10
Istanbul 10
Jiaxing 10
Norwalk 10
Paris 10
Shenzhen 10
Totale 9.332
Salva come PNG Salva come JPEG
Nome #
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 257
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 238
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 223
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 220
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 218
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 213
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 212
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 209
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 209
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 209
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 204
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 204
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 200
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 198
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 197
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 192
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 192
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 188
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 187
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 185
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 184
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 184
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 183
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 183
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 183
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 182
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 179
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 179
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 177
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 175
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 167
A risk prediction score for invasive mold disease in patients with hematological malignancies 166
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 165
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 164
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 163
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 162
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 156
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 155
Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies 154
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 154
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 154
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 151
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 151
Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B 148
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 143
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 142
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 140
Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters. 140
Retrospective cohort analysis of liposomal amphotericin b nephrotoxicity in patients with hematological malignancies 140
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 139
Dexamethasone plus rituximab yieldshigher sustained response rates than dexamethasone monotherapy in adultswith primary immune thrombocytopenia 139
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 138
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 137
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 136
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 135
Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. 134
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 134
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 133
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. 133
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 132
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 131
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 130
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 129
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. 128
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 127
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 127
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 127
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 125
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 125
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 124
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 122
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 120
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. 119
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 117
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 116
The CD47 pathway is deregulated in human immune thrombocytopenia 113
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. 109
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 107
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 106
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 106
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 105
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 104
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 100
null 98
null 96
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 96
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 93
Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis 91
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 91
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 89
null 86
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 86
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 86
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 83
Sinonasal risk factors for the development of invasive fungal sinusitis in hematological patients: Are they important? 56
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase 55
Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura 52
Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases 43
Prompt plasma-exchange treatment and coma reversibility in two patients with thrombotic thrombocytopenic purpura 38
Totale 14.532
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.946
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.946
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021519 0 0 0 0 0 0 0 0 0 66 53 400
2021/20221.577 78 43 91 187 127 71 38 103 53 183 334 269
2022/20231.856 174 270 102 249 122 162 47 125 323 79 125 78
2023/2024554 40 92 45 65 44 95 9 40 18 37 38 31
2024/20252.184 121 278 180 196 284 118 147 101 74 150 109 426
2025/20264.700 409 400 457 379 530 259 466 323 1.111 366 0 0
Totale 14.646